Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Dec 11, 2023 11:35am
143 Views
Post# 35777895

RE:RE:Options

RE:RE:OptionsThe 240,000 options with a strick price of $1.74 as shown on SEDI are a bit fishy.
The were granted in December 2013 and I can't quite match the share price at that time with the strike price of the options, even with accounting for the future reverse split. My thinking now is that those options are actually priced at about 9 x 1.74 so perhaps we can ignore them as worthless.

But there are still 175,000 options with a strike price of $1.45 and these expire in two days, on Wednesday December 13th. I am certain that MC has no interest in holding 175,000 shares of this sinking ship!

I predict that MC will be hitting the ATM full throttle over the next two days in a selfish effort to drive the price down below $1.50 CDN at which time he can avoid the future financial pain of holding shares in ONC. His hope would be to have his December 13th options expire worthless (because he would be in a position of having to hold the shares if converted). He likely knows better than anyone that dreams of a P3 in any indication are dwindling fast and almost unachievable for this POS after 25 years of mediocrity.
<< Previous
Bullboard Posts
Next >>